US20260174884
2026-06-25
Human necessities
A61K47/6455
Vaccines have long been crucial in preventing diseases by inducing immunity through agents resembling pathogens. Traditional vaccines often include weakened or killed microbes to stimulate antibody production. The current development introduces a novel approach using messenger RNA (mRNA) to create vaccines, aiming for safer and more effective disease prevention.
The approach involves administering a composition that includes mRNA encoding an antigen, encapsulated in lipid nanoparticles (LNPs). This formulation can be delivered in various ways, such as subcutaneously, intradermally, or intramuscularly, to induce specific immune responses. The mRNA can encode proteins or peptides and may include modified nucleotides to enhance efficacy.
The dosing regimen is flexible, allowing for single or multiple doses to achieve the desired immune response. Doses can range from 0.1 μg to 100 mg, adjusted based on body weight and the intended immune response. Administration schedules may vary, with doses potentially given weekly or at specific intervals to optimize the immune response.
Lipid nanoparticles serve as the delivery vehicle for the mRNA, potentially comprising various lipid types, including cationic, helper, and cholesterol-based lipids. The composition of these nanoparticles is critical for ensuring stability and efficient delivery of the mRNA to target cells, such as lymph nodes or lymphocytes, where antigen expression occurs.
The administration of these mRNA vaccines results in the expression of the antigen, leading to antigen-specific antibody and T-cell responses. These responses can be measured through various assays and are detectable within days to weeks post-administration. This innovative method offers a promising alternative to traditional vaccines, with potential applications in a wide range of diseases.